2003
Morbidity and mortality in obstructive sleep apnea syndrome 1: Effect of treatment on cardiovascular morbidity
SHEPERTYCKY M, AL‐BARRAK M, KRYGER M. Morbidity and mortality in obstructive sleep apnea syndrome 1: Effect of treatment on cardiovascular morbidity. Sleep And Biological Rhythms 2003, 1: 15-28. DOI: 10.1046/j.1446-9235.2003.00003.x.Peer-Reviewed Original ResearchObstructive sleep apnea syndromeSevere cardiovascular outcomesCongestive heart failureIschemic heart diseaseCardiovascular morbidityHeart failureCardiovascular outcomesPulmonary hypertensionSystemic hypertensionHeart diseaseCardiac arrhythmiasContinuous positive airway pressure (CPAP) treatmentPositive airway pressure treatmentOngoing population-based studyLarge ongoing trialsUntreated OSAS patientsIndependent risk factorDevelopment of hypertensionEpisodes of apneaSleep apnea syndromePopulation-based studyEffect of treatmentNocturnal hypoxemiaOSA patientsOSAS patients
2002
Cardiovascular medication use in patients with undiagnosed obstructive sleep apnoea
Otake K, Delaive K, Walld R, Manfreda J, Kryger M. Cardiovascular medication use in patients with undiagnosed obstructive sleep apnoea. Thorax 2002, 57: 417. PMID: 11978918, PMCID: PMC1746332, DOI: 10.1136/thorax.57.5.417.Peer-Reviewed Original ResearchConceptsMore daily dosesCardiovascular diseaseSystemic hypertensionMedication usePrescribed medicationsDaily dosesMore prescriptionsOdds ratioSleep apnoea/hypopnoea syndromeUndiagnosed obstructive sleep apnoeaObstructive sleep apnoeaCardiovascular medication useCongestive heart failureUse of medicationsGeneral population controlsOSAS casesMore medicationsSecondary preventionAngina pectorisHeart failureSleep apnoeaMedication costsSuch medicationsMyocardial infarctionOSAS diagnosis